About GB Sciences (OTCMKTS:GBLX)
GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:GBLX
- CUSIP: N/A
- Web: growblox.com/
- Market Cap: $28.74 million
- Outstanding Shares: 127,746,000
- 50 Day Moving Avg: $0.25
- 200 Day Moving Avg: $0.27
- 52 Week Range: $0.21 - $0.65
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: $54,099.00
- Price / Sales: 531.30
- Book Value: $0.06 per share
- Price / Book: 3.95
- EBITDA: ($10,010,000.00)
- Net Margins: -5,761.07%
- Return on Equity: -158.06%
- Return on Assets: -100.57%
- Average Volume: 216,165 shs.
Frequently Asked Questions for GB Sciences (OTCMKTS:GBLX)
What is GB Sciences' stock symbol?
GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."
How were GB Sciences' earnings last quarter?
GB Sciences Inc (OTCMKTS:GBLX) posted its earnings results on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. GB Sciences had a negative return on equity of 158.06% and a negative net margin of 5,761.07%. View GB Sciences' Earnings History.
Who are some of GB Sciences' key competitors?
Some companies that are related to GB Sciences include Capricor Therapeutics (CAPR), IntelGenx Technologies Corp. (IGXT), OmniComm Systems (OMCM), PERPETUAL ENERGY I COM NPV (POST REV SPLIT) (PMGYF), Invivo Therapeutics Holdings Corp (NVIV), OptimizeRx Corp. (OPRX), One Group Hospitality (STKS), Generation Next Franchise Brands (VEND), HealthWarehouse.com (HEWA), Genius Brands International (GNUS), Trimel Pharmaceuticals Corp. (TRLPF), Deep Down (DPDW), Omni-Lite Industries Canada (OLNCF), Noble Roman's (NROM), Sierra Monitor Corp. (SRMC), Destiny Media Technologies (DSNY), Trxade Group (TRXD) and usell.com (USEL).
Who are GB Sciences' key executives?
GB Sciences' management team includes the folowing people:
- John Poss, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer
- Leslie Bocskor, Independent Vice Chairman of the Board
- Ksenia Griswold, Chief Financial Officer, Vice President
- Andrea Small-Howard Ph.D., Chief Science Officer, Director
- Shane Terry, Independent Director
How do I buy GB Sciences stock?
Shares of GB Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GB Sciences' stock price today?
MarketBeat Community Rating for GB Sciences (OTCMKTS GBLX)MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of GB Sciences stock can currently be purchased for approximately $0.23.
Consensus Ratings for GB Sciences (OTCMKTS:GBLX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for GB Sciences (OTCMKTS:GBLX)
Analysts' Ratings History for GB Sciences (OTCMKTS:GBLX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for GB Sciences (OTCMKTS:GBLX)Earnings History by Quarter for GB Sciences (OTCMKTS GBLX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for GB Sciences (OTCMKTS:GBLX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for GB Sciences (OTCMKTS:GBLX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for GB Sciences (OTCMKTS:GBLX)Insider Trades by Quarter for GB Sciences (OTCMKTS:GBLX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/4/2017||Craig Ellins||Insider||Sell||100,000||$0.26||$26,000.00|| |
|10/6/2016||Lazarus Management Co Llc||Major Shareholder||Sell||785,000||$0.31||$243,350.00|| |
|10/8/2014||Lazarus Management Co Llc||Major Shareholder||Buy||77,700||$0.69||$53,613.00|| |
|10/2/2014||Lazarus Management Co Llc||Major Shareholder||Buy||39,605||$0.85||$33,664.25|| |
|9/29/2014||Lazarus Management Co Llc||Major Shareholder||Buy||64,000||$0.90||$57,600.00|| |
|9/17/2014||Lazarus Management Co Llc||Major Shareholder||Buy||47,640||$0.76||$36,206.40|| |
|8/27/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||46,625||$1.05||$48,956.25|| |
|8/1/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||39,800||$1.24||$49,352.00|| |
|7/30/2014||Israel Opportunities F Lazarus||Major Shareholder||Buy||87,077||$1.24||$107,975.48|| |
|7/2/2014||Lazarus Investment Partners Ll||Major Shareholder||Buy||269,632||$1.19||$320,862.08|| |
|6/2/2014||Lazarus Management Co Llc||Major Shareholder||Buy||1,000,000||$0.50||$500,000.00|| |
Headline Trends for GB Sciences (OTCMKTS:GBLX)
Latest Headlines for GB Sciences (OTCMKTS:GBLX)
Loading headlines, please wait.
GB Sciences (GBLX) Chart for Monday, October, 23, 2017